Author Affiliations: Departments of Medicine (Dr Hajjar and Ms Brown), Preventive Medicine (Dr Mack), and Neurology (Dr Chui), Division of Geriatric, Hospital, and General Internal Medicine, University of Southern California, Los Angeles, California.
We appreciate the interest Oprisiu et al expressed in our recent publication.1 We agree that a clinical trial comparing the cognitive effects of angiotensin-converting enzyme inhibitors with angiotensin receptor blockers (ARBs) in older adults with hypertension is critical. In this respect, we have recently completed a pilot study comparing lisinopril, candesartan, and an active control with hydrochlorothiazide.2 In this pilot trial, we found a superior positive effect of ARBs relative to angiotensin-converting enzyme inhibitors on cognitive function. We are planning a larger trial to confirm and extend these initial findings.
Ihab Hajjar, Lauren Brown, Wendy J. Mack, Helena Chui. Alzheimer Pathology and Angiotension Receptor Blockers. JAMA Neurol. 2013;70(3):414. doi:10.1001/jamaneurol.2013.1689